(Q38206366)

31 August 2017

1 reference

14 July 2021

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment (English)

1 reference

31 August 2017

1 reference

25 September 2020

1 reference

ChEBI release 2020-05-28

ChEBI ID

84050

tumor microenvironment

1 reference

alkylating antineoplastic agent

8 September 2020

1 reference

25 September 2020

tetrahydroisoquinolines

1 reference

14 July 2021

1 reference

14 July 2021

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Paola Allavena

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

N Badri

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

C M Galmarini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

22 April 2014

1 reference

British Journal of Cancer

31 August 2017

12 August 2014

8 references

12 March 2019

19 March 2019

3 April 2019

7 August 2019

2 October 2019

8 September 2020

25 September 2020

14 July 2021

9 references

12 March 2019

19 March 2019

3 April 2019

7 August 2019

2 October 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

8 September 2020

25 September 2020

14 July 2021

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

646-650

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

31 May 2020

copyright license

8 references

12 March 2019

19 March 2019

3 April 2019

7 August 2019

2 October 2019

8 September 2020

25 September 2020

on focus list of Wikimedia project

14 July 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Prospects and challenges for the development of new therapies for Ewing sarcoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

A review of trabectedin (ET-743): a unique mechanism of action.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Macrophage diversity enhances tumor progression and metastasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Targeting DNA repair as a promising approach in cancer therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Tumour-educated macrophages promote tumour progression and metastasis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Ecteinascidin-743 inhibits activated but not constitutive transcription.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Mode of action of trabectedin in myxoid liposarcomas.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

The intriguing patterns of tumor response to trabectedin

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Role of homologous recombination in trabectedin-induced DNA damage

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134488

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

31 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2014.149

Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2014.149

Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2014.149

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/24755886

12 December 2020

inferred from PubMed ID database lookup

13 years of trabectedin, 5 years of Yondelis®: what have we learnt?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24755886

12 December 2020

inferred from PubMed ID database lookup

Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24755886

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/BJC.2014.149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

31 May 2020

1006338022

0 references

Fatcat ID

release_lqgncyss3fg45cacbff5nn5rhy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lqgncyss3fg45cacbff5nn5rhy

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

PubMed publication ID

24755886

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755886%20AND%20SRC:MED&resulttype=core&format=json